Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Jameson, Elisabeth ^a   Jones, Simon ^a   Wraith, James E ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; LARONIDASE; PLACEBO; ANTIBODY; LEVO IDURONIDASE;

ALLERGIC REACTION; ANTIBODY PRODUCTION; ANTIBODY TITER; CLINICAL EFFECTIVENESS; DRUG SAFETY; ENZYME REPLACEMENT; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HURLER SYNDROME; HYPOVENTILATION; LIVER WEIGHT; MORTALITY RATE; NUMBERS NEEDED TO TREAT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIX MINUTE WALK TEST; SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COGNITION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEVER; HEADACHE; HEIGHT; HOT FLUSH; INFUSION RELATED REACTION; LUNG FUNCTION TEST; MORTALITY; OUTCOME ASSESSMENT; RASH; RESPIRATORY FUNCTION; ADOLESCENT; ADULT; BLOOD; CHILD; CLASSIFICATION; FEMALE; IMMUNOLOGY; MALE; MUCOPOLYSACCHARIDOSIS I; PROCEDURES; RARE DISEASES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT; METHODOLOGY; RARE DISEASE;

ADOLESCENT; ADULT; ANTIBODIES; CHILD; ENZYME REPLACEMENT THERAPY; FEMALE; HUMANS; IDURONIDASE; MALE; MUCOPOLYSACCHARIDOSIS I; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84899130837     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009354.pub2     Document Type: Review

References (25)

1. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al.Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009;123(1):229-40.
2. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al.Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics 2004;144(5):581-8.
3. de Rue MH, Boelens JJ, Das AM, Jones SA, van der Ledd JH, Mahlaoui N, et al.Enzyme replacement therapy and / or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet Journal of Rare Disease 2011;6(55):1-9.
4. Giugliani R, Rojas VM, Martins AM, Valadares ER, Clarke JTR, Goes JEC, et al.A dose-optimisation trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism 2009;96(1):13-9.
5. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, et al.Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genetics in Medicine 2005;7(2):143-6.
6. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al.Enzyme-replacement therapy in mucopolysaccharidosis I. New England Journal of Medicine 2001;344(3):182-8.
7. Pitz S, Ogun O, Bajbouj M, Arash L, Schulze-Frenking G, Beck M. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy. Archives of Ophthalmology 2007;125(10):1353-6.
8. Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007;120(1):e37-46.
9. Wynn RF, Mercer J, Page, J, Carr TF, Jones S, Wraith JE. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. Journal of Pediatrics 2009;154(1):135-9.
10. American Thoracic Society. Standardization of spirometry, 1994 update. American Thoracic Society. American Journal of Respiratory and Critical Care Medicine 1995;152:1107-36.
11. Visual Rx. Online NNT Calculator. www.nntonline.net/. Cates C, (accessed 01 June 2013).
12. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al.The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Archives of Internal Medicine 2000;160(18):2835-43.
13. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al.Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009;123(1):229-40.
14. D'Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al.Diagnosis and treatment in mucopolysaccharidosis I: findings from the MPS I Registry. European Journal of Pediarics 2012;171(6):911-9.
15. ® (Laronidase). www.aldurazyme.com/pdf/az_us_hc_pi.pdf (accessed 25 September 2013).
16. Higgins JPT, Altman DG, Sterne JAC, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistencies in meta-analyses. 2003 BMJ;327(7414):557-60.
18. Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
19. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalance of lysosomal storage disorders. JAMA 1999;281(3):249-54.
20. Genzyme Corporation. MPS I Registry. www.lsdregistry.net/mpsiregistry/ (accessed 06 July 2011).
21. Muenzer J, Wraith JE, Clarke LA and the International Consensus Panel on the Management and Treatment of Mucopolysaccharidosis I. Mucolpolysaccharidosis I: management and treatment guidelines. Pediatrics 2009;123(1):19-29.
22. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet, Sly W, et al. editor(s). The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill, 2001:3421-52.
23. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
24. Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genetics in Medicine 2003;5(4):286-94.
25. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al.Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. American Journal of Medicine 2002;113(2):112-9.